Out-licensing

Messenger Biopharma will not develop its own mRNA products and will not produce mRNA.

We are eager to out-license our technologies to pharmaceutical companies for the development of mRNA vaccines and therapies, and to CDMOs for the production of mRNA using at least one of our technologies.

Last news

business-model

Messenger Biopharma in the newspaper “La Montagne”

posted February 15, 2016

“Messenger Biopharma in the newspaper “La ...Read More